Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DNV 3837

Drug Profile

DNV 3837

Alternative Names: DNV 3681; DNV-3837; MCB-3681; MCB-3837; Oxaquin

Latest Information Update: 10 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Morphochem AG
  • Developer Biovertis AG; Deinove; Evotec SE
  • Class Antibacterials; Oxazolidinones; Quinolones
  • Mechanism of Action DNA topoisomerase inhibitors; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Clostridium difficile infections
  • Phase I Bacterial infections
  • Discontinued Nosocomial infections

Most Recent Events

  • 02 Aug 2019 Phase-II clinical trials in Clostridium difficile infections in USA (IV) (NCT03988855)
  • 26 Jun 2019 DNV 3837 is still in phase I development for Bacterial infections in Germany
  • 25 Jun 2019 Antimicrobial data from preclinical studies presented at the American Society for Microbiology (ASM-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top